Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Hereditary Hemorrhagic Telangiectasia: early-phase trial registry

2 of 8 indexed Hereditary Hemorrhagic Telangiectasia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 2 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Hereditary Hemorrhagic Telangiectasia: 8 US clinical trials tracked, 2 recruiting.

Hereditary Hemorrhagic Telangiectasia is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Cure HHT, running 2 of these trials.

Enrollment posture brief

Registry condition hereditary-hemorrhagic-telangiectasia

OPEN 2 | RECR 25% | LATE 0 | EARLY 5 | RANK #2176 | SPON 2

Nearest open-share peer: Abdominal Pain (25% recruiting · 20 trials)

Activity, Motor75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%Hereditary Hemorrhagic T (th…25%
Open-enrollment share among volume-matched conditions near Hereditary Hemorrhagic Telangiectasia

Hereditary Hemorrhagic Telangiectasia lists 2 open slots (25% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hereditary Hemorrhagic Telangiectasia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hereditary Hemorrhagic Telangiectasia is recruiting below its size-band peers.

    2 of 8 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Hereditary Hemorrhagic Telangiectasia research.

    Cure HHT accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Hereditary Hemorrhagic Telangiectasia trials plan to enrol fewer than 100 people.

    Median target enrolment is 70 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.

  4. Hereditary Hemorrhagic Telangiectasia splits between interventional and observational designs.

    5 interventional and 3 observational studies make up this index (62.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 22

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2

Top Sponsors

Named interventions

Most-linked intervention names on Hereditary Hemorrhagic Telangiectasia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Sclerotherapy Drug
1 trials
Bevacizumab (Avastin®) Drug
1 trials
Ultra-low dose chest CT Diagnostic test
1 trials
ALN-6400 Drug
1 trials
Pazopanib Drug
1 trials
Placebo oral capsule Drug
1 trials
Pomalidomide Drug
1 trials
Standard Treatment Other
1 trials

US sites by state

Facility locations filed on Hereditary Hemorrhagic Telangiectasia trials. A trial with sites in several states counts in each.

Minnesota 5 trials
Ohio 4 trials
Massachusetts 4 trials
California 4 trials
Utah 3 trials
North Carolina 3 trials
Missouri 3 trials
Georgia 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hereditary Hemorrhagic Telangiectasia page

8 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Hereditary Hemorrhagic Telangiectasia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Cure HHT sponsors the most Hereditary Hemorrhagic Telangiectasia trials on record, review their full trial history before evaluating a specific study. See Cure HHT's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hereditary Hemorrhagic Telangiectasia condition card totals 8 registered trials; most-linked intervention Sclerotherapy; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.